What is PLX's P/E ratio?

Protalix Biotherapeutics Inc (PLX) currently trades at a P/E ratio of 9.16.

Protalix Biotherapeutics Inc reports a Return on Equity (ROE) of 22.81%.

What is PLX's dividend yield?

Protalix Biotherapeutics Inc offers a dividend yield of 0.00%.

What is PLX's Quality Score?

Our AI rates PLX's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PLX?

Our AI Timing Score for PLX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PLX belong to?

Protalix Biotherapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange

Protalix Biotherapeutics Inc (PLX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

PLX AI Analysis Summary

Our AI summary for PLX: Protalix Biotherapeutics Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 9.16, ROE of 22.81%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PLX

Protalix Biotherapeutics Inc

US:NYSE MKT STOCK Healthcare >> Biotechnology News 83

USD 2.37

0.05 (2.16%) Day Change

Watchlist Portfolio Compare Chart

9.16

P/E

0.02

D/E

22.8%

ROE

15.0%

ROA

0.00%

Div Yield

-0.05

PEG

PROTALIX BIOTHERAPEUTICS INC
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 2.37 Price 0.05 (2.16%) Day Change	NEWS SCORE: 83

PLX, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	83
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.37
PBV / Sector	2.84 / 44,022.72
Earning Per Share	0.19

PE / Sector	9.16 / 19.17 GREAT
PEG or PE/Growth / Sector	-0.05 / 1.24
Average 1M Daily Value	1.29 M GREAT
Average 1W Daily Value	1.66 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

62%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	20.07 / 98.24 GREAT
NPM Average (%) / Sector	-1.12 / -1,697.63
NPM Change Average (%) / Sector	-196.40 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	14.98 / 185,260.96
ROA Average (%) / Sector	-1.19 / 36,684.70
ROA Change Average (%) / Sector	-195.96 / 422,221.66
ROE (%) / Sector	22.81 / 243,762.23 GOOD
ROE Average (%) / Sector	36.19 / 48,758.47 GREAT
ROE Change Average (%) / Sector	-180.82 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:42
Symbol	PLX
Name	PROTALIX BIOTHERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	80.57 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	190.95 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2 University Plaza, Hackensack, NJ, United States, 07601

Phone: 201 696 9345

Website: https://www.protalix.com

Employees: 226

Sector: Healthcare >> Biotechnology

Description: Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.